Search the website

Fulltext search

Search results

Categories

Human Remove Human filter Veterinary (24) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Orphan designations Remove Orphan designations filter Summaries of opinion (12) Apply Summaries of opinion filter Withdrawn applications (35) Apply Withdrawn applications filter Referrals (18) Apply Referrals filter Direct healthcare professional communication (19) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (10) Apply Yes filter

Authorisation status

Authorised (545) Apply Authorised filter Refused (2) Apply Refused filter Withdrawn (70) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (15) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (117) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (25) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (11) Apply Yes filter

Compliance procedure number

Orphan disease / condition

Orphan decision number

Orphan designation status

Positive (107) Apply Positive filter

Medicine type

Additional monitoring Remove Additional monitoring filter Generic Remove Generic filter Accelerated assessment (100) Apply Accelerated assessment filter Biosimilar (77) Apply Biosimilar filter Conditional approval (85) Apply Conditional approval filter Exceptional circumstances (65) Apply Exceptional circumstances filter Orphan medicine (427) Apply Orphan medicine filter

Related medicine

Therapeutic area

Topic

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

883 results

Remove all filtersRemove all filters

Medicine type Additional monitoring Remove Additional monitoring filter Generic Remove Generic filter

Medicine Orphan designations Remove Orphan designations filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter

Categories Human Remove Human filter

Sort by

List item

Human medicine European public assessment report (EPAR): Aybintio (updated)

bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020, , , Revision: 2, Authorised, Last updated: 06/04/2021
List item

Human medicine European public assessment report (EPAR): Ivozall (updated)

clofarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 14/11/2019, , Revision: 2, Authorised, Last updated: 31/03/2021
List item

Human medicine European public assessment report (EPAR): Keytruda (updated)

Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urologic Neoplasms, Squamous Cell Carcinoma of Head and Neck
Date of authorisation: 17/07/2015, , Revision: 32, Authorised, Last updated: 31/03/2021
List item

Human medicine European public assessment report (EPAR): Levetiracetam Teva (updated)

levetiracetam, Epilepsy
Date of authorisation: 25/08/2011, , Revision: 17, Authorised, Last updated: 31/03/2021
List item

Human medicine European public assessment report (EPAR): Matever (updated)

levetiracetam, Epilepsy
Date of authorisation: 03/10/2011, , Revision: 22, Authorised, Last updated: 31/03/2021
List item

Human medicine European public assessment report (EPAR): Pioglitazone Teva Pharma (updated)

pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 26/03/2012, , Revision: 12, Authorised, Last updated: 31/03/2021
List item

Human medicine European public assessment report (EPAR): Lenalidomide Mylan (updated)

lenalidomide, Multiple Myeloma
Date of authorisation: 18/12/2020, , Revision: 1, Authorised, Last updated: 31/03/2021
List item

Human medicine European public assessment report (EPAR): Epclusa (updated)

Sofosbuvir, velpatasvir, Hepatitis C, Chronic
Date of authorisation: 06/07/2016, , , Revision: 14, Authorised, Last updated: 31/03/2021
List item

Human medicine European public assessment report (EPAR): Hulio (updated)

adalimumab, Hidradenitis Suppurativa, Psoriasis, Crohn Disease, Uveitis, Arthritis, Rheumatoid, Colitis, Ulcerative, Spondylitis, Ankylosing, Arthritis, Psoriatic
Date of authorisation: 16/09/2018, , , Revision: 5, Authorised, Last updated: 30/03/2021
List item

Human medicine European public assessment report (EPAR): Comirnaty (updated)

Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020, , , Revision: 4, Authorised, Last updated: 30/03/2021
List item

Human medicine European public assessment report (EPAR): COVID-19 Vaccine Moderna (updated)

CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), COVID-19 virus infection
Date of authorisation: 06/01/2021, , , Revision: 1, Authorised, Last updated: 30/03/2021
List item

Human medicine European public assessment report (EPAR): Trazimera (updated)

trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/07/2018, , , Revision: 7, Authorised, Last updated: 29/03/2021
List item

Human medicine European public assessment report (EPAR): Cometriq (updated)

cabozantinib, Thyroid Neoplasms
Date of authorisation: 21/03/2014, , , , Revision: 21, Authorised, Last updated: 29/03/2021
List item

Human medicine European public assessment report (EPAR): Ocrevus (updated)

ocrelizumab, Multiple Sclerosis
Date of authorisation: 08/01/2018, , Revision: 10, Authorised, Last updated: 29/03/2021
List item

Human medicine European public assessment report (EPAR): Axumin (updated)

Fluciclovine (18F), Prostatic Neoplasms, Radionuclide Imaging
Date of authorisation: 21/05/2017, , Revision: 11, Authorised, Last updated: 25/03/2021
List item

Human medicine European public assessment report (EPAR): Staquis (updated)

Crisaborole, Dermatitis, Atopic
Date of authorisation: 27/03/2020, , Revision: 3, Authorised, Last updated: 25/03/2021
List item

Human medicine European public assessment report (EPAR): Telmisartan Teva (updated)

telmisartan, Hypertension
Date of authorisation: 25/01/2010, , Revision: 11, Authorised, Last updated: 25/03/2021
List item

Human medicine European public assessment report (EPAR): Zoledronic Acid Hospira (updated)

zoledronic acid monohydrate, Hypercalcemia
Date of authorisation: 19/11/2012, , Revision: 17, Authorised, Last updated: 25/03/2021
List item

Human medicine European public assessment report (EPAR): Strensiq (updated)

asfotase alfa, Hypophosphatasia
Date of authorisation: 28/08/2015, , , , Revision: 14, Authorised, Last updated: 25/03/2021
List item

Human medicine European public assessment report (EPAR): Lenvima (updated)

lenvatinib mesilate, Thyroid Neoplasms
Date of authorisation: 28/05/2015, , , Revision: 15, Authorised, Last updated: 25/03/2021
List item

Human medicine European public assessment report (EPAR): Deferiprone Lipomed (updated)

Deferiprone, Iron Overload, beta-Thalassemia
Date of authorisation: 19/09/2018, , Revision: 3, Authorised, Last updated: 25/03/2021
List item

Human medicine European public assessment report (EPAR): Lemtrada (updated)

alemtuzumab, Multiple Sclerosis
Date of authorisation: 12/09/2013, , , Revision: 11, Authorised, Last updated: 25/03/2021
List item

Human medicine European public assessment report (EPAR): Bortezomib Fresenius Kabi (updated)

bortezomib, Multiple Myeloma
Date of authorisation: 14/11/2019, , Revision: 4, Authorised, Last updated: 24/03/2021
List item

Human medicine European public assessment report (EPAR): Rizmoic (updated)

Naldemedine tosilate, Constipation
Date of authorisation: 18/02/2019, , Revision: 5, Authorised, Last updated: 24/03/2021
List item

Human medicine European public assessment report (EPAR): Bortezomib Hospira (updated)

bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016, , Revision: 10, Authorised, Last updated: 24/03/2021

Load more

883 results

Human medicine European public assessment report (EPAR): Aybintio (updated)

Human medicine European public assessment report (EPAR): Ivozall (updated)

Human medicine European public assessment report (EPAR): Keytruda (updated)

Human medicine European public assessment report (EPAR): Levetiracetam Teva (updated)

Human medicine European public assessment report (EPAR): Matever (updated)

Human medicine European public assessment report (EPAR): Pioglitazone Teva Pharma (updated)

Human medicine European public assessment report (EPAR): Lenalidomide Mylan (updated)

Human medicine European public assessment report (EPAR): Epclusa (updated)

Human medicine European public assessment report (EPAR): Hulio (updated)

Human medicine European public assessment report (EPAR): Comirnaty (updated)

Human medicine European public assessment report (EPAR): COVID-19 Vaccine Moderna (updated)

Human medicine European public assessment report (EPAR): Trazimera (updated)

Human medicine European public assessment report (EPAR): Cometriq (updated)

Human medicine European public assessment report (EPAR): Ocrevus (updated)

Human medicine European public assessment report (EPAR): Axumin (updated)

Human medicine European public assessment report (EPAR): Staquis (updated)

Human medicine European public assessment report (EPAR): Telmisartan Teva (updated)

Human medicine European public assessment report (EPAR): Zoledronic Acid Hospira (updated)

Human medicine European public assessment report (EPAR): Strensiq (updated)

Human medicine European public assessment report (EPAR): Lenvima (updated)

Human medicine European public assessment report (EPAR): Deferiprone Lipomed (updated)

Human medicine European public assessment report (EPAR): Lemtrada (updated)

Human medicine European public assessment report (EPAR): Bortezomib Fresenius Kabi (updated)

Human medicine European public assessment report (EPAR): Rizmoic (updated)

Human medicine European public assessment report (EPAR): Bortezomib Hospira (updated)